Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.
Animal model
Doxorubicin
Drug delivery
Pharmacokinetics
Transarterial chemoembolization
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
accepted:
12
04
2021
pubmed:
17
4
2021
medline:
9
4
2022
entrez:
16
4
2021
Statut:
ppublish
Résumé
The purpose of this study was to compare intra-tumoral drug delivery, pharmacokinetics, and treatment response after doxorubicin (DOX) conventional (c-) versus drug-eluting embolic (DEE-) transarterial chemoembolization (TACE) in a rabbit VX2 liver tumor model. Twenty-four rabbits with solitary liver tumors underwent c-TACE (n = 12) (1:2 water-in-oil emulsion, 0.6 mL volume, 2 mg DOX) or DEE-TACE (n = 12) (130,000 70-150 µm 2 mg DOX-loaded microspheres). Systemic, intra-tumoral, and liver DOX levels were measured using mass spectrometry up to 7-day post-procedure. Intra-tumoral DOX distribution was quantified using fluorescence imaging. Percent tumor necrosis was quantified by a pathologist blinded to treatment group. Lobar TACE was successfully performed in all cases. Peak concentration (C
Identifiants
pubmed: 33861419
doi: 10.1007/s13346-021-00985-8
pii: 10.1007/s13346-021-00985-8
doi:
Substances chimiques
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1117Informations de copyright
© 2021. Controlled Release Society.
Références
Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–51.
doi: 10.1007/s00270-009-9750-0
Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105(1):59–68.
doi: 10.1093/jnci/djs464
Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol. 1991;13(1):120–7.
doi: 10.1016/0168-8278(91)90873-A
Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992;70(3):585–90.
Namur J, Wassef M, Millot JM, Lewis AL, Manfait M, Laurent A. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol. 2010;21(2):259–67.
doi: 10.1016/j.jvir.2009.10.026
Dreher MR, Sharma KV, Woods DL, Reddy G, Tang Y, Pritchard WF, et al. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol. 2012;23(2):257–64 e4.
Zhang SHC, Li Z, Yang Y, Bao T, Chen H, Zou Y, Song L. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv. 2017;24(1):101–7.
Gupta S, Wright KC, Ensor J, Van Pelt CS, Dixon KA, Kundra V. Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. Cardiovasc Intervent Radiol. 2011;34(5):1021–30.
doi: 10.1007/s00270-011-0154-6
Choi JWCH, Park JH, Baek SY, Chung JW, Kim DD, Kim HC. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads. PLoS One. 2014;9(12):e115898.
doi: 10.1371/journal.pone.0115898
Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol. 2012;198(3):692–9.
doi: 10.2214/AJR.11.7066
Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81.
doi: 10.1016/j.jhep.2006.10.020
Rous P, Beard JW. The Progression to Carcinoma of Virus-Induced Rabbit Papillomas (Shope). J Exp Med. 1935;62(4):523–48.
doi: 10.1084/jem.62.4.523
Kidd JG, Rous P. A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. J Exp Med. 1940;71(6):813–38.
doi: 10.1084/jem.71.6.813
Virmani S, Harris KR, Szolc-Kowalska B, Paunesku T, Woloschak GE, Lee FT, et al. Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs. J Vasc Interv Radiol. 2008;19(6):931–6.
doi: 10.1016/j.jvir.2008.02.019
Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173(1):83–91.
doi: 10.1016/S0304-3835(01)00667-X
Hamuro M, Nakamura K, Sakai Y, Nakata M, Ichikawa H, Fukumori Y, et al. New oily agents for targeting chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1999;22(2):130–4.
doi: 10.1007/s002709900348
Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13(9 Pt 2):S211–21.
doi: 10.1016/S1051-0443(07)61789-8
Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017;24(5):101–5.
pubmed: 29386977
pmcid: 5772820
Easty DM, Easty GC. Establishment of an in vitro cell line from the rabbit VX2 carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;39(3):333–7.
doi: 10.1007/BF02892859
Yoneda T, Kitamura M, Ogawa T, Aya S, Sakuda M. Control of VX2 carcinoma cell growth in culture by calcium, calmodulin, and prostaglandins. Cancer Res. 1985;45(1):398–405.
pubmed: 3917374
Namur J, Citron SJ, Sellers MT, Dupuis MH, Wassef M, Manfait M, et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol. 2011;55(6):1332–8.
doi: 10.1016/j.jhep.2011.03.024
Gaba RC, Baumgarten S, Omene BO, van Breemen RB, Garcia KD, Larson AC, et al. Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. J Vasc Interv Radiol. 2012;23(2):265–73.
doi: 10.1016/j.jvir.2011.10.022
Parvinian A, Casadaban LC, Gaba RC. Development, growth, propagation, and angiographic utilization of the rabbit VX2 model of liver cancer: a pictorial primer and “how to” guide. Diagn Interv Radiol. 2014;20(4):335–40.
doi: 10.5152/dir.2014.13415
Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol. 1997;4(4):275–82.
doi: 10.1016/S1076-6332(97)80029-3
Casadaban L, Parvinian A, Gaba RC. Effects of doxorubicin (DOX) delivery on tumor necrosis after drug-eluting bead transarterial chemoembolization (DEB-TACE). J Vasc Interv Radiol. 2015;26(2):S18.
Doxorubicin Material Safety Data Sheet [Available from: http://datasheets.scbt.com/sc-200923.pdf .
Loading of DC Beads using Doxorubicin Powder 10mg in vial 2019 [Available from: http://bead.btg-im.com/products/uk-322/dcbead-3/dcbead-loading-debdox .
Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2 Pt 1):335–42.
doi: 10.1097/01.RVI.0000195323.46152.B3
Bourget P, Delouis JM. Review of a technic for the estimation of area under the concentration curve in pharmacokinetic analysis. Therapie. 1993;48(1):1–5.
pubmed: 8356539
Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, et al. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol. 2008;19(10):1483–9.
doi: 10.1016/j.jvir.2008.06.017
Manautou JE, Silva VM, Hennig GE, Whiteley HE. Repeated dosing with the peroxisome proliferator clofibrate decreases the toxicity of model hepatotoxic agents in male mice. Toxicology. 1998;127(1–3):1–10.
doi: 10.1016/S0300-483X(98)00013-4
Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry–the red, brown, and blue technique. Vet Pathol. 2014;51(1):42–87.
doi: 10.1177/0300985813505879
Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2(5):278–89.
doi: 10.1016/S1470-2045(00)00323-5
Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, et al. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget. 2020;in press.
Idee JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88(3):530–49.
doi: 10.1016/j.critrevonc.2013.07.003
Gaba RC, Schwind RM, Ballet S. Mechanism of action, pharmacokinetics, efficacy, and safety of transarterial therapies using ethiodized oil: preclinical review in liver cancer models. J Vasc Interv Radiol. 2018;29(3):413–24.
doi: 10.1016/j.jvir.2017.09.025
Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther. 1993;53(5):555–61.
doi: 10.1038/clpt.1993.69
de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol. 2016;39(3):334–43.
doi: 10.1007/s00270-015-1208-y
Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):75–85.
doi: 10.1016/j.clinre.2016.05.013
Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297–302.
doi: 10.14740/jocmr2496w
Khabbaz RC, Huang YH, Smith AA, Garcia KD, Lokken RP, Gaba RC. Development and angiographic use of the rabbit VX2 model for liver cancer. J Vis Exp. 2019(143).